TIZIMLI SKLERODERMIYADA QIZILO'NGACH (OZIQ-OVQAT YO'LI) ZARARLANISHI

Sh.E Madiyorov

Toshkent Davlat Tibbiyot Universiteti

Sagatova D.R

Toshkent Davlat Tibbiyot Universiteti

Keywords: sklerodermiya, qizilo'ngach zararlanishi, gastroezofageal reflyuks, ezofageal dismotiliya, yuqori rezolyutsiyali manometriya, proton pompasi ingibitorlari, fibroz, vaskulopatiya, autoimmun jarayonlar, Barrett qizilo'ngachi, o'pka fibrozi, prokinetiklar, buzpiron, endoskopiya, pH-metriya.

---

Abstract

Tizimli sklerodermiya (SSc) - ko'p tizimli autoimmun kasallik bo'lib, teri va ichki a'zolar fibrozini keltirib chiqaradi. Oshqozon-ichak trakti, xususan qizilo'ngach zararlanishi bemorlarning 90% da uchraydi. Zararlanish peristaltika buzilishi, pastki qizilo'ngach sfinkterining (PQS) gipotoniyasi va gastroezofageal reflyuks kasalligi (GERK) bilan bog'liq, hayot sifatini pasaytiradi va o'limni oshiradi. Patogenez vaskulopatiya, fibroz va yallig'lanishni o'z ichiga oladi, ishemiya, mushak atrofiyasi va nerv zararlanishiga olib keladi. Ushbu tezisda SSc da qizilo'ngach zararlanishining patogenezi, klinik ko'rinishlari, diagnostikasi va davolash usullari ko'rib chiqiladi. Maqsad - ilmiy manbalarga asoslanib, muammoni baholash va yangi terapiyalarni taklif qilish. Natijalar aperistaltika va GERK ni 60-80% da ko'rsatadi, o'pka fibrozi bilan bog'liq. Kasallik endoteliyn ko'payishi, trombotsitlar faollashuvi va TGF-β ta'siri orqali kuchayadi. Davolashda proton pompasi ingibitorlari (PPI) va prokinetiklar asosiy, ammo buzpiron, vonoprazan va transkutan elektr nerv stimulatsiyasi (TENS) istiqbolli. Tezis SSc bemorlarida qizilo'ngach zararlanishini erta aniqlash va boshqarish bo'yicha tavsiyalar beradi, etnik farqlar va epigenetik omillarni hisobga olgan holda.

---

References

1. Li, B., Yan, J., Pu, J., Tang, J., Xu, S., & Wang, X. (2021). Esophageal dysfunction in systemic sclerosis: An update. Rheumatology and Therapy, 8(4), 1535-1549. https://doi.org/10.1007/s40744-021-00382-0

2. Denaxas, K., Ladas, S. D., & Karamanolis, G. P. (2018). Evaluation and management of esophageal manifestations in systemic sclerosis. Annals of Gastroenterology, 31(2), 165-170. https://doi.org/10.20524/aog.2018.0228

3. Voulgaris, T. A., & Karamanolis, G. P. (2021). Esophageal manifestation in patients with scleroderma. World Journal of Clinical Cases, 9(20), 5408-5419. https://doi.org/10.12998/wjcc.v9.i20.5408

4. Arif, T., Masood, Q., Singh, J., & Hassan, I. (2015). Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: A prospective comparative hospital based study. BMC Gastroenterology, 15, Article 12. https://doi.org/10.1186/s12876-015-0241-2

5. Shreiner, A. B., Murray, C., Denton, C., & Khanna, D. (2016). Gastrointestinal manifestations of systemic sclerosis. Journal of Scleroderma and Related Disorders, 1(3), 247-256. https://doi.org/10.5301/jsrd.5000219

6. Ghani, S., Serraj, I., Salihoun, M., Acharki, M., & Kabbaj, N. (2020). Esophageal motility disorders in systemic sclerosis. Pan African Medical Journal: Clinical Medicine, 2, Article 108. https://doi.org/10.11604/pamj-cm.2020.2.108.19998

7. Lock, G., Holstege, A., Lang, B., & Schölmerich, J. (1997). Gastrointestinal manifestations of progressive systemic sclerosis. The American Journal of Gastroenterology, 92(5), 763-771. https://doi.org/10.1111/j.1572-0241.1997.00763.x

8. Fulp, S. R., & Castell, D. O. (1990). Scleroderma esophagus. Dysphagia, 5(3), 134-141. https://doi.org/10.1007/BF02412607

9. Hara, M., Ueha, R., Sato, T., Goto, T., Yoshizaki, A., Sumida, H., Sato, S., & Yamasoba, T. (2023). Clinical risk factors for dysphagia and esophageal dysmotility in systemic sclerosis. Journal of Clinical Medicine, 12(10), Article 3448. https://doi.org/10.3390/jcm12103448

10. Roman, S., & Mion, F. (2011). Esophageal dysmotility associated with systemic sclerosis: A high-resolution manometry study. Diseases of the Esophagus, 24(5), 299-304. https://doi.org/10.1111/j.1442-2050.2010.01150.x